Marshall Irby, M.D.
NPI 1679560411 · Pulmonary Disease Physician · Monroe, LA
Enrolled with Medicare as Practitioner - Internal Medicine · source: CMS PECOS Public Provider Enrollment (2026.04.01)
Provider details
- NPI number
- 1679560411
- Entity type
- Individual
- Primary specialty
- Pulmonary Disease PhysicianAllopathic & Osteopathic Physicians
- Credential
- M.D.
- Sex
- Male
- Sole proprietor
- Yes
- License
- 08027R (LA)
Specialties & taxonomies
Allopathic & Osteopathic Physicians
Profile Score
A profile completeness & documented-activity index — NOT a quality, outcomes, or patient-satisfaction rating.
- Registry tenure25% of score
20 yrs in NPPES registry
- Profile completeness25% of score
100% of core fields populated
- Practice footprint15% of score
1 documented practice location
- Medicare service volume (vs. specialty peers)25% of score
1,260 Medicare services, 2024 (ranked within specialty)
- Open Payments transparency10% of score
Has Open Payments disclosures (2024)
Medicare volume is ranked against active providers in the same specialty. Signals a provider has no public data for (e.g. Medicare claims) are left out of the score entirely — never counted as zero — so providers without that data are not penalized. See the full formula and weights in our .
What this provider does (Medicare)
Based on Medicare fee-for-service claims, 2024; not all care is captured.
| Service (HCPCS) | Medicare services | Typical Medicare-allowed (2024) |
|---|---|---|
| Established Patient Office Or Other Outpatient Visit With Moderate Level of Decision Making, If Using Time, 30 Minutes Or More99214 | 712 | $111 |
| Test to Measure Expiratory Airflow and Volume94010 | 144 | $23 |
| Test to Determine Lung Volumes Using Sensors94726 | 144 | $46 |
| Test to Examine How Well the Lungs Exchange Gases94729 | 144 | $46 |
| New Patient Office Or Other Outpatient Visit With a High Level of Medical Decision Making, If Using Time, 60 Minutes Or More99205 | 79 | $192 |
| Established Patient Office Or Other Outpatient Visit With High Level of Medical Decision Making, If Using Time, 40 Minutes Or More99215 | 37 |
What this provider prescribes (Medicare Part D)
Top drugs by Medicare Part D claim volume, 2024 · 25 distinct drugs on file.
| Drug | Part D claims (2024) | Beneficiaries |
|---|---|---|
| Fluticasone/Umeclidin/Vilanterbrand: Trelegy Ellipta | 225 | 48 |
| Azithromycin | 213 | 62 |
| Tiotropium Br/Olodaterol Hclbrand: Stiolto Respimat | 202 | 34 |
| Albuterol Sulfatebrand: Albuterol Sulfate Hfa | 156 | 56 |
| Tiotropium Bromidebrand: Spiriva Respimat | 117 | 31 |
| Umeclidinium Brm/Vilanterol Trbrand: Anoro Ellipta | 112 | 22 |
Transparency — industry payments
Based on CMS Open Payments, 2024; not all care is captured.
$501 across 25 records (Open Payments 2024)
Open Payments discloses payments and transfers of value (meals, travel, consulting, research, royalties) from drug and device makers to providers. This is a transparency signal, not a verdict — such payments are legal and common, and their presence is neither an endorsement nor a criticism. Source: CMS Open Payments, program year 2024.
Practice location
Mailing address
Registry dates
- Enumerated
- 2005-10-05
- Last updated
- 2008-01-16
Source: CMS NPPES Data Dissemination (June 2026). NPI Central is not affiliated with CMS. Data is provided as-is from the public registry.